• DEVENEZ MEMBRE
    Pour un accès complet à theheart.org
    À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.

    L'abonnement est gratuit !
    Inscrivez-vous maintenant !
    Obtenez un accès limité de 30 jours aux articles de heartwire
    Professionnel de la santé   Oui Non
    Obtenez un accès limité !

Resource Center

Your Opinion Counts
What's New
Abstract
Abstracts
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.
DeFronzo RA, Abdul-Ghani M. Am J Cardiol. 2011;108(3 Suppl):3B-24B.
Abstract
Abstracts
Fasting Might Not Be Necessary Before Lipid Screening: A Nationally Representative Cross-sectional Study.
Steiner MJ, Skinner AC, Perrin EM. Pediatrics. 2011. [Epub ahead of print]
Abstract
Abstracts
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Barter PJ, Rye KA, Tardif JC, et al. Circulation. 2011;124:555-562.
Abstract
Abstracts
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF, Davidson MH, Robinson JG, et al. Diabetes Obes Metab. 2011. [Epub ahead of print]
Abstract
Abstracts
Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.
Jenkins DJ, Jones PJ, Lamarche B, et al. JAMA. 2011;306:831-839.
Abstract
Abstracts
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.
Buitrago-Lopez A, Sanderson J, Johnson L, et al. BMJ. 2011;343:d4488
Abstract
Abstracts
Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) educational program.
Tocci G, Ferrucci A, Guida Pet al. Clin Cardiol. 2011;34:560-566.
Abstract
Abstracts
Obesity phenotype and cardiovascular changes.
Park J, Kim SH, Cho GY, et al. J Hypertens. 2011;29:1765-1772.
Abstract
Abstracts
Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals.
Voulgari C, Tentolouris N, Dilaveris P, et al. J Am Coll Cardiol. 2011;58:1343-1350.
Abstract
Abstracts
Fenofibrate: a review of its use in dyslipidaemia.
McKeage K, Keating GM. Drugs. 2011;71:1917-1946.